Patents Examined by Theodore J. Criares
  • Patent number: 6617361
    Abstract: A protocol for prevention of Alzheimer's disease onset is described. The protocol involves stimulating the implicit memory, followed by continuing such stimulation in conjunction with psychological treatments followed by continuing said stimulation of the implicit memory and, in addition, stimulating the explicit memory. Use of this protocol results in a permanent replacement of undesirable behaviors with desirable ones.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: September 9, 2003
    Assignee: Be Able, LLC
    Inventor: Mark H. Eig
  • Patent number: 6616935
    Abstract: The present invention relates to the utilisation of water-insoluble linear poly-&agr;-glucan as UV filter, e.g., in sun protection products or in cosmetic as well as medical preparations. The invention also relates to a sun protection product which contains a biotechnically produced, water-insoluble linear poly-&agr;-glucan as UV filter.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: September 9, 2003
    Assignee: Celanese Ventures GmbH
    Inventors: Holger Bengs, Alfred Braunagel
  • Patent number: 6613788
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 2, 2003
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6613757
    Abstract: Cardiovascular disease, including preeclampsia in pregnant women and hypertension in both women and men, are prevented or treated by administering thereto prostacyclin or a prostacyclin analog in combination with one or both of an estrogen and a progestin, which combination is also useful for HRT in peri- and post-menopausal women.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: September 2, 2003
    Assignee: Board of Regents, The University of Texas System
    Inventors: Robert E. Garfield, Kristof Chwalisz
  • Patent number: 6613800
    Abstract: A method and composition for treating psoriasis, eczema, seborrheic dermatitis, and possibly arthritis. The present invention involves treatment of these conditions with an oral administration of a mixture comprised of three primary ingredients: fumaric acid and/or fumarate compounds, inorganic nickel compound(s) such as nickel sulfate, and inorganic bromide compound(s) such as potassium bromide.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: September 2, 2003
    Inventor: Steven A. Smith
  • Patent number: 6613767
    Abstract: A stable aqueous solution of folinic acid of up to about 400 mg/ml, which does not crystallize at refridgeration temperatures, is obtained by preparing an aqueous solution of sodium folinate.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: September 2, 2003
    Assignee: Pharmachemie B.V.
    Inventors: Alfred James Nijkerk, Johanna M. P. Vermeer
  • Patent number: 6610313
    Abstract: The present invention discloses improved lysophospholipids composition having water-solubility in order to solve a conventional problem accompanying only the use of LPE as an anti-aging lysophospholipid caused by water-insoluble property thereof, comprising subsidiary lysophospholipid components, that is, LPI and LPC other than LPE to inhibit aging processional lysophospholipids, thereby forming an enhanced water-soluble lysophospholipids composition conveniently useable in plants and/or animals applications.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 26, 2003
    Assignee: Doosan Corporation
    Inventors: GukHoon Chung, Young-Lae Yang, Ui C Koh
  • Patent number: 6610750
    Abstract: A method of treating osteoarthritis, which is effective not only at targeting the symptoms of the disease, but also in interrupting, preventing, and controlling cartilage destruction, to thereby favorably alter the course of the disease, comprising the administration of an effective amount of rhein or a rhein derivative, preferably diacerein, either alone or in combination with at least one member selected from the group consisting of analgesics, antipyretics, cortico-steroids, anti-inflammatory agents, cyclooxygenase-2 inhibitors, and inflammatory cytokine inhibitors, to a subject in need of such treatment.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: August 26, 2003
    Assignee: Laboratoires Negma
    Inventors: Suzy Charbit, Francois Schutze, Alain Taccoen, Jean-Pierre Pelletier, Diego Provvedini
  • Patent number: 6610206
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: August 26, 2003
    Assignee: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. van Schalkwijk, James J. Cole
  • Patent number: 6605622
    Abstract: The present invention provides compounds that are useful for inhibiting the proliferation of fungi. The compounds are estrogenic derivatives, such as 2ME2, or anti-estrogenic compounds. The compounds may be used for treating infections of fungi in humans and animals, or to prevent or inhibit the growth of fungi on any surface.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: August 12, 2003
    Assignee: EntreMed, Inc.
    Inventors: Shawn J. Green, Adonia Papathanassiu
  • Patent number: 6596733
    Abstract: Nitric oxide scavengers, such as dithiocarbamate-containing compounds, are used to reduce side effects caused by therapeutic administration of nitric oxide sources by administering the nitric oxide scavenger(s) to the subject after the therapeutic effect of the nitric oxide source has been achieved. For example, the nitric oxide source can be coadministered with the nitric oxide scavenger, with the latter formulated in a time release vehicle selected to delay release of the scavenger for a period of time sufficient to ensure that the therapeutic goal of the nitric oxide source has been achieved before release of the scavenger. Formulations and kits, including a bubble pack with pairwise arrangement of unit doses of a desired nitric oxide source and nitric oxide scavenger, are also provided.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: July 22, 2003
    Assignee: Medinox, Inc.
    Inventor: Ching-San Lai
  • Patent number: 6592880
    Abstract: Method for inhibition of sorbate-induced brown discolorations in cosmetic compositions and foodstuffs, and color-stabilized formulations containing sorbate preservative. The invention relates to a method for visual and sensorial stabilization of foodstuffs and cosmetic compositions containing sorbate preservative, which comprises adding allantoin or allantoin and citrates to these products as browning inhibitors.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: July 15, 2003
    Assignee: Aktiengesellschaft
    Inventor: Martin Jager
  • Patent number: 6593313
    Abstract: Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: July 15, 2003
    Assignee: Vivus, Inc.
    Inventors: Virgil A. Place, Leland F. Wilson, Paul C. Doherty, Jr., Mark S. Hanamoto, Alfred P. Spivack, Neil Gesundheit, Sean R. Bennett
  • Patent number: 6593372
    Abstract: The present invention is based on the discovery that nitric oxide (NO) is an important growth regulator in an intact developing organism. In particular, the present invention relates to a method of increasing in a mammal a population of hematopoietic stem cells which are capable of undergoing normal hematopoiesis, differentiation and maturation in hematopoietic tissue, wherein the hematopoietic tissue is contacted with multiple doses of at least one inhibitor of NO, such as one or more inhibitors of nitric oxide synthase (NOS), thereby producing hematopoietic tissue having an increased population of hematopoietic stem cells which are capable of undergoing normal hematopoiesis, differentiation and maturation. The present invention also relates to a method of increasing a population of cells in S phase in a tissue of a mammal, comprising contacting the tissue with multiple doses of at least one inhibitor (one or more) of NO, such as an inhibitor of NOS.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: July 15, 2003
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Grigori N. Enikolopov, Natalia I. Peunova, Boris A. Kuzin, Hollis Cline, Tatyana Michurina
  • Patent number: 6593369
    Abstract: Topical application of a prostaglandin directly to the clitoris is effective for enhancing female sexual desire and responsiveness.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 15, 2003
    Assignee: Vivus, Inc.
    Inventor: Gary W. Neal
  • Patent number: 6593370
    Abstract: A topical capsaicin preparation for the treatment of painful cutaneous disorders and neural dysfunction is disclosed. The preparation contains a nonionic, amphoteric or cationic surfactant in an amount effective to eliminate or substantially ameliorate burning pain caused by capsaicin.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: July 15, 2003
    Assignee: Maruishi Pharmaceutical Co., Ltd.
    Inventors: Takashi Tamura, Urao Kawakami, Yuichi Teratani, Masakazu Yoshimura, Masahiko Seto
  • Patent number: 6593368
    Abstract: The present invention is directed to novel combinations of anti-epileptic compounds that demonstrate pain alleviating properties, with compounds selected from the group consisting of analgesics, N-methyl-D aspartate (NMDA) receptor antagonists and non-steroidal anti-inflammatory drugs (NSAIDS) and pharmaceutical compositions comprising same.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: July 15, 2003
    Assignee: Warner-Lambert Company
    Inventors: Leslie Magnus-Miller, Douglas A. Saltel
  • Patent number: 6589975
    Abstract: Novel uses of biologically active bis-heterocyclic e.g. bis-indole alkaloid compounds which have improved activity are disclosed. Pharmaceutical compositions containing the compounds are also disclosed. Specifically, the novel utility pertains to the anti-immunogenic and neurogenic inflammatory properties exhibited by the bis-indole compounds and their analogs.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: July 8, 2003
    Assignees: The Regents of the University of California, Harbor Branch Oceanographic Inst.
    Inventors: Robert S. Jacobs, Claudia E. Moya, Amy E. Wright
  • Patent number: 6586416
    Abstract: Co-administration of a channel blocking epithelial sodium channel (ENaC) blocker in conjunction with a mineralocorticoid receptor inhibitor makes it possible to achieve desired lowering of blood pressure with use in the range of 20% to 75% or less of the presently used dosage of the mineralocorticoid receptor inhibitor (MRI), thus avoiding many of the deleterious side effects usually associated with administration of an MRI. As little as 10% of the usual dosage of MRI may, in some cases, be efficacious. The most commonly used ENaC blocker now in use is amiloride. The most commonly used inhibitors of the mineralocorticoid receptor are precursors of canrenone.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: July 1, 2003
    Inventor: James K. Bubien
  • Patent number: 6586457
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: July 1, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Shun-Ichi Harada, Mohamed MacHwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young